# 1st half reported revenues ahead of expectations for Allergy Therapeutics plc

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-plc-h1-reported-revenues-ahead-expectations/412721511
- Published: 2017-01-19T07:21:29+00:00
- Author: Giles Arbor

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical company specialising in allergy vaccines,
today provides an update on trading for the six months ended 31 December 2016 ahead
of its unaudited interim results to be announced on 29 March 2017.

– H1 reported revenues ahead of expectations
 – Regulatory update: Pollinex Quattro
clinical development programs to proceed as planned

Financials

Reported revenues for the six months ended 31 December 2016 are expected to be £
40.4m (2015: £29.0m), representing 17.9% organic growth at constant currency* (39.3%
growth on a reported basis, aided by the impact on euro revenues of the weak pound).
This growth reflects continued strong momentum across the majority of the Company’s
key markets. In a flat European market, the Company is fuelling its growth by increasing
market share in most of its key markets. The main contributions in terms of net 
sales growth were generated in Germany, Austria, Spain and The Netherlands. In terms
of products, growth is being provided across the whole portfolio, with the Company’s
ultra-short course aluminium-free therapies being the main contributor. The Board
expects continuing growth in the second half of the year.

The strength of the euro against sterling has also led to higher overheads and R&
D costs as most of these costs are incurred in continental Europe in euros but are
reported in sterling.

The cash balance at 31 December 2016 was £27.8m (£33.2m at 31 December 2015).

Regulatory

Further to the Company’s announcement on 27 June 2016, the Company has held discussions
with the US regulatory authorities in relation to its US Grass MATA MPL programme
and is proceeding as planned with the safety trial (G104) in the USA and the Phase
II conjunctival provocation test dose selection study (G205) in Europe in 2017, 
ahead of the planned pivotal Phase III trial (G306).

> **Commenting on the positive trading update, Manuel Llobet, Chief Executive Officer
> of Allergy Therapeutics plc, said:** “The Company’s progress continues according
> to our long-term plans both in gaining market share in our main territories and
> with our clinical development. Our 18% top line organic growth in real terms reflects
> the quality of our products, technology and team, and the underlying convenience
> of our ultra-short course vaccines. We are excited by the prospects of the Company
> as we continue expanding our operations in Europe, progressing our development
> pipeline and moving forward with a world-class portfolio of allergy vaccines. 
> We are confident about the full year and look forward to updating shareholders
> on further progress throughout 2017.”

*Constant currency uses prior year weighted average exchange rates to translate 
current year foreign currency denominated revenue to give a year on year comparison
excluding the effects of foreign exchange movements.

 

Zeus Capital said that the company has highlighted a period of strong growth in 
revenue, driven through gains in market share and also currency movements. AGY anticipates
that it will report H1 revenues of approximately £40.4m (we had expected £35.4m).
Importantly, the company has confirmed that its clinical development plans as outlined
last year for Pollinex Quattro (PQ) Birch and PQ Grass have been agreed with regulators
in Europe and the USA. The company had cash of £27.8m at December 31st 2016. We 
have revised our financial forecasts for the coming years with increases in sales
and gross margins as well as overheads. Our risk-adjusted fair value estimate now
stands at 69p per share (previously 66p).
 Sales: During the period sales are expected
to have grown to approximately £40.4m (39.3% growth ‘as reported’, 17.9% at constant
currency) driven by a number of separate factors. Firstly, in broadly flat markets
AGY continues to gain market share in Germany, Austria, Spain and The Netherlands
based on the strengths of its PQ-based vaccines. Secondly, market share has grown
following certain weaknesses experienced by key competitors in Europe including 
Allergopharma (continuing to lose market share through strategic organisational 
uncertainties), ALK (injectable vaccine supply constraints following investments
necessary to upgrade manufacturing facilities), and Stallergenes (French manufacturing
issues led to loss of market share which has not been regained from AGY, particularly
in the UK). Thirdly, Euro strength against GBP has favoured AGY’s sales, the majority
of which are Euro denominated.

Margins: We expect gross margins to have increased given that the majority of Cost
of Goods for its PQ-based named-patient products relates to labour costs in Worthing(
UK). Raw materials, even those imported from outside the UK, represent only a small
portion of product costs.

Overheads: Currency movements during the period are also likely to have affected
overheads, much of which are also Euro denominated including R&D (mainly conducted
in European countries) and Sales, Marketing and Distribution (around 90% in Europe).

Forecasts: With these movements in mind, we have revised our sales and overhead 
forecasts for FY2017 (to June 30) and subsequent years as shown opposite. In addition,
we have increased our R&D spending forecasts reflecting the new certainty of development
with confirmation of acceptance by the regulators for the company to go ahead with
its clinical trials as planned.

Comment: Allergy Therapeutics plc full year is normally heavily H1 weighted as this
is the peak prescribing and treatment period for seasonal allergies in Europe. The
indicated H1 sales performance, which the company will report in more detail on 
March 29th, has been stronger than expected and operationally, the company is now
positioned to enact its clinical development plans for PQ Birch (phase III in Europe)
and PQ Grass (phase II in the USA) following agreement with the respective regulators.
Our revised forecasts take into account the improved market share of AGY in many
European countries which we believe are likely to continue to grow based on the 
competitive strengths of its product portfolio. The company has invested significantly
in its European subsidiaries and we believe this should enable it to continue to
trade successfully in the longer term following the UK’s eventual separation from
the EU. Ultimately however, we expect more than 50% of the company’s revenues are
going to be derived from product sales in non-EU markets, particularly the USA.

Share on:
